Brown, Lisle/Cummings’s DexCom DXCM Stock Holding History

Brown, Lisle/Cummings’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3	Closed	-$205	–	783
2025 Q1	$205	Buy	+3	New	+$245	﹤0.01%	778

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Brown, Lisle/Cummings's DXCM Position: Q2 2025 in Review

Brown, Lisle/Cummings sold out of DexCom (DXCM) in Q2 2025, closing a stake of 3 shares — an estimated $205 sold.

Brown, Lisle/Cummings first reported a position in DXCM in Q1 2025 and held it in 1 quarter. The position peaked at $205 in Q1 2025. 939 funds tracked by Wall St. Rank hold DXCM as of Q2 2025.

Brown, Lisle/Cummings reported no remaining DexCom position as of Q2 2025 after selling out during the quarter.
Brown, Lisle/Cummings sold 3 DexCom shares in Q2 2025, an estimated $205.
Brown, Lisle/Cummings first reported a position in DexCom in Q1 2025 and held it in 1 quarter.
Brown, Lisle/Cummings's DexCom position peaked at $205 in Q1 2025.
939 funds tracked by Wall St. Rank held DexCom as of Q2 2025.

Based on Brown, Lisle/Cummings's 13F filing for Q2 2025, filed 16 Jul 2025.